Alkermes to start Phase III of Aripiprazole Lauroxil NanoCrystal Dispersion for schizophrenia

In October, Alkermes plc (NASDAQ:ALKS) said it will begin a double-blind, U.S. Phase IIIb trial of Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD) plus Aristada aripiprazole

Read the full 242 word article

User Sign In